Real-Life Advantages and Limits of Baricitinib for the Late Treatment of Adults Hospitalized with COVID-19
Authors:
- Mariacristina PolisenoMPMariacristina Poliseno
- Donato LacedoniaDLDonato Lacedonia
- Mariangela NiglioMNMariangela Niglio
- Federica De GregorioFGFederica De Gregorio
- Graziano Antonio MinafraGMGraziano Antonio Minafra
- Terence CampaninoTCTerence Campanino
- Giulio GigantiGGGiulio Giganti
- Giulia SciosciaGSGiulia Scioscia
- Teresa Antonia SantantonioTSTeresa Antonia Santantonio
- Maria Pia Foschino BarbaroMBMaria Pia Foschino Barbaro
- Sergio Lo CaputoSCSergio Lo Caputo
Open Access
Abstract
Baricitinib, a reversible Janus-associated kinase-inhibitor, is approved for treating COVID-19, combined with Dexamethasone and, eventually, with Remdesivir (RDV). This retrospective cohort study assesses the real-life advantages and limits of Baricitinib in the current pandemic scenario. Data of all patients consecutively hospitalized with moderate/severe COVID-19 between 1 October 2021 and 31 March 2022 were retrospectively collected and described according to the treatment received (Baricitinib, Baricitinib + RDV, none). We performed survival analyses to estimate the 21-day probability of Intensive Care Unit (ICU) admission, death, and composite. We built multivariate Cox regression models to identify ICU admission/death predictors among patients’ features. Of 111 subjects, 28 received Baricitinib, 21 received Baricitinib + RDV, and 62 could not be treated due to pre-existing conditions. Treated patients had a comparable risk of death (HR 0.50, 95% C.I. 0.20–1.26, p = 0.14) but remarkably lower risk of 21-day ICU admission (H.R., 0.10, 95% C.I., 0.01–0.86, p = 0.03), regardless of the type of treatment received. At multivariable analysis, older age was the only predictor of ICU admission/death (HR 1.14, 95% C.I. 1.03–1.26, p ≤ 0.01).Although effective, the high prevalence of elderly, co-morbid patients limits Baricitinib use in the current pandemic setting.Keywords
This publication has 23 references indexed in Scilit:
- Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, ItalyJAMA, 2020
- Baricitinib for COVID-19: a suitable treatment?The Lancet Infectious Diseases, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritisDrugs in Context, 2019
- Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in TreatmentThe Journal of Rheumatology, 2018
- Sepsis in Older AdultsInfectious Disease Clinics of North America, 2017
- IPC: Professional Type 1 Interferon-Producing Cells and Plasmacytoid Dendritic Cell PrecursorsAnnual Review of Immunology, 2005
- Early events in signalling by interferonsTrends in Biochemical Sciences, 1993